Table 3. Characteristics of Sample of Crohn’s Patients by Anti-A4Fla2IgG Category.
| Low anti-A4Fla2 IgG | High anti-A4Fla2 IgG | P value | |
|---|---|---|---|
| Age, mean (SD) | 45.5 (15.6) | 41.1 (15.7) | 0.1170a |
| Sex, N (%) | 0.1596b | ||
| Females | 51 (58.6%) | 34 (70.8%) | |
| Males | 36 (41.4%) | 14 (29.2%) | |
| Race, N (%) | 0.0058c | ||
| Caucasians | 61 (70.1%) | 21 (43.8%) | |
| African Americans | 24 (27.6%) | 25 (52.1%) | |
| Others | 2 (2.2%) | 2 (4.2%) | |
| Duration of disease in years, mean (SD) | 9.0 (10.8) | 10.7 (11.5) | 0.1410d |
| Steroid use, N (%) | 35 (40.7%) | 22 (45.8%) | 0.5642b |
| Tobacco use, N (%) | 19 (22.1%) | 11 (22.9%) | 0.9127b |
| TNF blocker use, N (%) | 53 (61.6%) | 34 (70.8%) | 0.2843b |
| VD use, N (%) | 14 (16.3%) | 6 (12.5%) | 0.5561b |
| UST use, N (%) | 23 (26.7%) | 13 (27.1%) | 0.9661b |
| Thiopurine, N (%) | 10 (11.6%) | 11 (22.9%) | 0.0848b |
| MTX, N (%) | 12 (14.0%) | 4 (8.3%) | 0.3361b |
| Crohn’s behavior, N (%) | 0.6640b | ||
| Penetrating | 31 (36.0%) | 21 (43.8%) | |
| Stricturing | 23 (26.7%) | 12 (25.0%) | |
| None | 32 (37.2%) | 15 (31.3%) | |
| Perianal, N (%) | 24 (27.9%) | 16 (33.3%) | 0.5104b |
| UGI, N (%) | 17 (19.8%) | 13 (27.1%) | 0.3300b |
| Crohn’s location, N (%) | 0.0245b | ||
| Ileal | 18 (20.7%) | 5 (10.4%) | |
| Colonic | 30 (34.5%) | 9 (18.8%) | |
| Ileocolonic | 38 (43.7%) | 34 (70.8%) | |
| BMI, mean (SD) | 26.9 (7.0) | 26.6 (7.6) | 0.8295a |
| Obesity, N (%) | 32 (37.2%) | 16 (33.3%) | 0.6537b |
| PPI use, N (%) | 31 (36.0%) | 11 (22.9%) | 0.1162b |
aTwo sample t-test; bChi-square; cFisher’s exact; dWilcoxon rank sum. SD: standard deviation; TNF: tumor necrosis factor; VD: vedolizumab; UST: ustekinumab; MTX: methotrexate; UGI: upper gastrointestinal; BMI: body mass index; PPI: proton pump inhibitor.